Brokers Set Expectations for Fennec Pharmaceuticals Inc.’s Q2 2024 Earnings (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRX) – Investment analysts at Capital One Financial dropped their Q2 2024 earnings estimates for shares of Fennec Pharmaceuticals in a report released on Monday, August 5th. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will earn ($0.24) per share for the quarter, down from their prior forecast of ($0.21). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $1.20 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.10) EPS and FY2024 earnings at $0.08 EPS.

Fennec Pharmaceuticals Price Performance

Shares of TSE:FRX opened at C$7.95 on Thursday. The company has a market capitalization of C$217.19 million, a PE ratio of 159.00 and a beta of 0.46. Fennec Pharmaceuticals has a 52 week low of C$7.80 and a 52 week high of C$15.43. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 6.93. The company has a 50 day moving average price of C$8.76 and a two-hundred day moving average price of C$11.43.

Fennec Pharmaceuticals (TSE:FRX) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share for the quarter, missing the consensus estimate of C$0.67 by C($0.11). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. The business had revenue of C$34.21 million for the quarter, compared to analyst estimates of C$14.19 million.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.